# AI-driven pilot platforms and computational pharmaceutics: accelerating innovation in small molecule drug development under industry 4.0 and 5.0 paradigms

## TL;DR

This paper reviews how AI and digital technologies are transforming pilot platforms for small molecule drug development, enhancing efficiency and sustainability in pharmaceutical manufacturing.

## Contribution

The paper provides a comprehensive analysis of AI-driven innovations in pilot-scale drug development platforms under Industry 4.0 and 5.0 paradigms.

## Key findings

- AI-driven process optimization and digital twin technologies are enhancing pharmaceutical pilot platforms.
- Integration of computational pharmaceutics and green chemistry is promoting sustainable drug development.
- Challenges like data-sharing limitations and outdated infrastructure hinder AI adoption in pilot systems.

## Abstract

In the era of artificial intelligence (AI) and Industry 4.0, pilot-scale platforms for small molecule chemical drugs are undergoing a transformative digital evolution. These platforms serve as a critical link between early-stage laboratory research and full-scale pharmaceutical manufacturing, ensuring process feasibility, scalability, and regulatory compliance. This review offers a comprehensive and forward-looking analysis of the structure, function, and strategic importance of pilot-scale systems within the modern pharmaceutical landscape. Focusing on the integration of AI and intelligent automation, the study highlights innovations such as AI-driven process optimization, predictive maintenance, data integration, digital twin technologies, and continuous manufacturing. These technologies are reshaping conventional production paradigms by enhancing efficiency, improving quality control, and reducing environmental impact. The convergence of computational pharmaceutics and green chemistry is also examined as a key driver of sustainable and intelligent drug development. Moreover, the review addresses the industry’s transition toward Industry 5.0, characterized by human-machine collaboration, data-centric innovation, and an emphasis on sustainability. Persistent challenges such as equipment standardization gaps, data-sharing limitations, and outdated infrastructure are critically discussed. Drawing from industrial case studies, academic research, and best practices, this paper explores both the opportunities and constraints associated with AI-enabled pilot platforms. Ultimately, the review aims to inform future strategies in digital pharmaceutical manufacturing by underscoring the importance of technological innovation, regulatory alignment, and collaborative ecosystems in advancing the development, efficiency, and sustainability of small molecule drug production.